Elevation Oncology, Inc. (ELEV) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
888 Seventh Avenue
Boston, NY 10106
United States of America (the)
Phone
716 371 1125
Sector
Healthcare
Industry
Biotechnology
Employees
34
First IPO Date
June 25, 2021
| Name | Title | Pay | Year Born |
| Joseph J. Ferra Jr. | Chief Executive Officer, President & Director | 931,579 | 1975 |
| Valerie Malyvanh Jansen | Chief Medical Officer | 685,941 | 1979 |
| Tammy Furlong | Chief Financial Officer & Secretary | 0 | 1972 |
| Biren Shah | Senior Vice President of Business & Corporate Development | 0 | N/A |
| Robert C. Yang | Senior Vice President & General Counsel | 0 | N/A |
| Ryan Bloomer | Senior Vice President of Technical Operations | 0 | N/A |
Elevation Oncology, Inc. is a clinical-stage biopharmaceutical company operating in the United States, committed to developing targeted cancer therapies for patients with specific genetic profiles. Its leading drug candidate is seribantumab, an anti-HER3 monoclonal antibody currently being evaluated in the Phase II CRESTONE trial. This study focuses on treating advanced solid tumors that harbor a neuregulin-1 fusion. The company was established in 2019 and is headquartered in New York, New York.